Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-519c-5p inhibitor
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
miR-519c-5p inhibitor is an antisense oligonucleotide or antagomir designed to target and inhibit microRNA-519c-5p (miR-519c-5p). In preclinical models of sepsis-associated acute kidney injury (SA-AKI), miR-519c-5p is delivered to renal macrophages via neutrophil-derived exosomes (TNF-Exo), where it suppresses the expression of tumor necrosis factor alpha-induced protein 3 (TNFAIP3/A20). This suppression enhances NEK7 K63-linked ubiquitination and activates the NLRP3 inflammasome, leading to macrophage pyroptosis and severe renal injury. Treatment with a miR-519c-5p inhibitor blocks this pathway, reducing macrophage pyroptosis, alleviating renal injury, and improving survival in sepsis mouse models.
- Other names
- anti-miR-519c-5panti-miR519c-5panti-miR 519c-5phsa-miR-519c-5p inhibitorhsa-miR519c-5p inhibitorhsa-miR 519c-5p inhibitormiR-519c-5p antagomirmiR519c-5p antagomirmiR 519c-5p antagomir
Beyond the preview
Go deeper on miR-519c-5p inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-519c-5p inhibitor.